江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会议资料 江苏浩欧博生物医药股份有限公司 二〇二五年九月 江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会 议资料 江苏浩欧博生物医药股份有限公司（688656） 2025 年第二次临时股东大会会议资料 为了维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会的顺 利进行，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司股东会规 则》以及《江苏浩欧博生物医药股份有限公司章程》《江苏浩欧博生物医药股份有限公司 股东大会议事规则》等相关规定，江苏浩欧博生物医药股份有限公司（以下简称"公司"） 特制定 2025 年第二次临时股东大会会议须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人员将对 出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，出席会议的股 东及股东代理人须在会议召开前 15 分钟到会议现场办理签到手续，并请按规定出示证券账 户卡、身份证明文件或企业营业执照/注册证书复印 ...

Core Points - The company is holding its second extraordinary general meeting of shareholders in 2025 to ensure the rights of all shareholders and maintain order and efficiency during the meeting [1][2] - The meeting will include discussions and voting on key proposals, including addressing unremedied losses and the election of independent directors [6][7] Meeting Procedures - Shareholders and their representatives must arrive at the meeting venue 30 minutes prior to the start to complete registration and present necessary identification documents [2][3] - The meeting will follow a predetermined agenda, and shareholders have the right to speak, inquire, and vote [2][3] - Voting will be conducted both on-site and online, with specific time frames for each method [5][6] Key Proposals - Proposal 1: Addressing unremedied losses that have reached one-third of the company's paid-in capital, with unallocated profits reported at -43.95 million yuan as of December 31, 2024 [6][7] - Proposal 2: Election of independent directors due to the expiration of terms for current independent directors, with candidates nominated and approved by the board [7][8]